Call for applicants, Editor Selection Committee

The ASCI is convening an Editor Selection Committee to identify and recommend a new Editor for JCI Insight, to succeed Howard Rockman, MD, whose term expires at the end of August 2019. The new Editor will serve a 5-year term, beginning September 1, 2019.

The Committee is, per the bylaws, constituted by members of the Publications Committee, which is presently as follows: Kieren Marr, W. Kimryn Rathmell, Lorraine Ware, Hossein Ardehali, Gordon Tomaselli, Howard Rockman, and Andrew Fontenot. Dr. Marr, who is the 2018-2019 ASCI President, will serve as Chair of the Committee.

The Committee seeks to fill two additional Committee seats and calls for applications from members. The Committee will become active in July 2018 and conclude its activity upon its recommendation of a candidate to the ASCI Council for consideration.

Members interested in serving must be available for an in-person meeting of the Committee on April 4, 2019 (in Chicago), when the Committee will interview finalists for Editor and determine its recommendation.

Applications consist of the following in a single PDF:

  • A summary (limit of 250 words) of the member’s research and training background
  • An explanation (limit of 500 words) of the member’s interest in and experience with editorial matters, and including comment about JCI Insight’s editorial focus
  • A full academic CV

Applications are due May 31, 2018, and must be sent via email to staff@the-asci.org. The committee will review applications and submit its recommended applicants to the Council for approval.

The ASCI’s 2018 Young Physician-Scientist Awards

The ASCI is pleased to recognize the 35 recipients of its 2018 Young Physician-Scientist Awards. The Awardees presented their work at the ASCI’s Food & Science Evening, on April 21, 2018, as part of the AAP/ASCI/APSA Joint Meeting, April 20-22, 2018.

Awardee Institution Abstract title
Ana Paula Abreu, MD, PhD Brigham and Women’s Hospital, Harvard Medical School MKRN3, a new player in the reproductive axis
Raag D. Airan, MD, PhD Stanford University Spatiotemporally precise and versatile noninvasive neuromodulation via focused ultrasonic drug uncaging
Francis J. Alenghat, MD, PhD University of Chicago Skap2 regulates atherosclerosis through macrophage polarization and efferocytosis
Vivek K. Arora, MD, PhD Washington University School of Medicine Bladder-cancer-associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial proliferation
Megan T. Baldridge, MD, PhD Washington University School of Medicine Transferable microbiota factor stimulates resistance to norovirus infection in immunodeficient mice
Scott W. Canna, MD University of Pittsburgh/Children’s Hospital of Pittsburgh Dysregulation of interleukin-18 diagnostically distinguishes and pathogenically promotes macrophage activation syndrome
Brian Curran Capell, MD, PhD Perelman School of Medicine, University of Pennsylvania KMT2D regulates p63 target enhancers to coordinate epithelial homeostasis
Kevin J. Cheung, MD Fred Hutchinson Cancer Research Center Tumor cell clustering promotes breast cancer metastasis by increasing apoptosis resistance and cell proliferation
Silvia S. Chiang, MD Alpert Medical School of Brown University/ Hasbro Children’s Hospital/ Center for International Health Research Barriers to the diagnosis of childhood tuberculosis: a qualitative study
Janet Chou, MD Boston Children’s Hospital Leucine-rich repeat–containing 8A (LRRC8A) is essential for T cell activation by non-hematopoietic antigen-presenting cells
Louis Jared Cohen, MD, MS Icahn School of Medicine at Mount Sinai Bacterial modulation of human glycans in inflammatory bowel disease
Kimberley Jane Evason, MD, PhD Huntsman Cancer Institute and University of Utah Serotonin in zebrafish liver development and tumorigenesis
Jennifer E. Flythe, MD, MPH University of North Carolina-Chapel Hill Failed target weight achievement associates with short-term hospital encounters
Robert David Guzy, MD, PhD University of Chicago Fibroblast growth factor 2 decreases bleomycin-induced pulmonary fibrosis through inhibition of fibroblast collagen production
Andrew M. Intlekofer, MD, PhD Memorial Sloan Kettering Cancer Center Acquired clinical resistance to IDH inhibition through in trans IDH2 mutations
Prasanna Jagannathan, MD Stanford University Impact of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy on risk of malaria in early childhood
Benjamin Levi, MD University of Michigan Tuning inflammation to improve musculoskeletal wound healing through modification of monocyte/macrophage Tgfb1
Piro Lito, MD, PhD Memorial Sloan Kettering Cancer Center Modeling the evolution of resistance to ERK signaling inhibitors at the single cell level
Steven E. Mansoor, MD, PhD Knight Cardiovascular Institute, Oregon Health and Science University Mechanisms of P2X receptor activation, desensitization, and antagonism­­­­
Jonathan J. Miner, MD, PhD Washington University Mouse models of Zika virus pathogenesis
Zaman Mirzadeh, MD, PhD Barrow Neurological Institute Perineuronal net formation in the hypothalamic arcuate nucleus-median eminence corresponds with the end of the critical period for AgRP/NPY neuron maturation
Chiadi Ericson Ndumele, MD, PhD Johns Hopkins University The association of longitudinal changes in metabolic syndrome with incident heart failure: the Atherosclerosis Risk in Communities (ARIC) study
Esther A. Obeng, MD, PhD St. Jude Children’s Research Hospital The nonsense-mediated decay pathway is a therapeutic vulnerability in myelodysplastic syndromes
Michael Joseph Ombrello, MD National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH IL1RN variation is associated with systemic juvenile idiopathic arthritis and predicts non-response to anakinra treatment
Cevher Ozcan, MD University of Chicago Mitochondrial mechanism of atrial fibrillation and novel therapies for primary prevention of the disease process
James R. Priest, MD Stanford University School of Medicine Rare inherited variants confer substantial risk for congenital heart disease in a large British cohort
Jarrad M. Scarlett, MD, PhD University of Washington Diabetes remission induced by the central action of fibroblast growth factor 1
Chetan Shenoy, MBBS University of Minnesota Long-term outcomes after detection of left ventricular thrombus by late gadolinium enhancement cardiovascular magnetic resonance imaging
Neeraj K. Surana, MD, PhD Boston Children’s Hospital Moving beyond microbiome-wide associations to causal microbe identification
David B. Sykes, MD, PhD Massachusetts General Hospital DHODH inhibition as differentiation therapy for acute myeloid leukemia: understanding the metabolic therapeutic window
Viviany R. Taqueti, MD, MPH Brigham and Women’s Hospital Coronary microvascular dysfunction is a better discriminator of cardiovascular risk than body mass index in obese patients
Sarah Kathleen Tasian, MD Children’s Hospital of Philadelphia and University of Pennsylvania Essential JAK, SRC, and PI3K signaling pathways regulate cell survival in human Ph-like acute lymphoblastic leukemia
Kirk J. Wangensteen, MD, PhD University of Pennsylvania Perelman School of Medicine Novel combination therapy for hepatocellular carcinoma identified by genetic screening
Melissa Y. Yeung, MD Harvard Medical School / Brigham and Women’s Hospital Identifying key regulators of B cell–mediated transplant tolerance
Lilei Zhang, MD, PhD Baylor College of Medicine KLF15 regulates the circadian susceptibility to ischemia reperfusion injury in the heart

Best Poster Award recipients

Each year, the ASCI recognizes three presenters with $1,000 Best Poster Awards. The 2018 Best Poster Award recipients are, from left, Drs. Guzy, Mansoor, and Canna.

Recipients of the 2018 Seldin~Smith Award for Pioneering Research: Anna Greka, MD, PhD, and Deepak Nijhawan, MD, PhD

Dr. Greka
Photo: Martin Adolfsson

Dr. Nijhawan

The American Society for Clinical Investigation (ASCI) is pleased to announce the recipients of the 2018 Donald Seldin~Holly Smith Award for Pioneering Research: Anna Greka, MD, PhD, and Deepak Nijhawan, MD, PhD.

Dr. Greka focuses on developing targeted treatments for kidney diseases, where there has been virtually no progress in the last 40 years. Her laboratory studies kidney podocytes, critical blood-filtering cells whose loss is responsible for progression to kidney failure. In 2013, Dr. Greka’s group identified TRPC5 as an important mediator of podocyte injury. In 2017, her team developed AC1903, a TRPC5-specific blocker, which protected podocytes from death and suppressed disease progression in multiple animal models of kidney disease. This discovery has formed the basis for precision therapies for kidney diseases, now in active development. Dr. Elizabeth Nabel, President of Brigham Health, who nominated Dr. Greka for this recognition, wrote that this latest work “has launched precision medicine for kidney disease — a long-awaited day in the field of nephrology.” Dr. Greka’s nomination was supported by Dr. Eric S. Lander, President and Founding Director of the Broad Institute of MIT and Harvard.

Dr. Nijhawan focuses on identifying targets for cancer treatment. In particular, his laboratory has investigated indisulam and CD437, identified as anticancer agents in the 1990s but not subsequently developed because their targets were poorly understood. In 2016, Dr. Nijhawan’s laboratory identified the target of CD437, followed in 2017 by identification of the target of indisulam and of cancer-cell variants most susceptible to its effects. This has created new interest in these agents, which are now in active development in collaboration with Dr. Nijhawan’s team. Dr. Steven L. McKnight, Distinguished Chair in Basic Biomedical Research at UT Southwestern, nominated Dr. Nijhawan. “These discoveries, I predict, constitute the most promising avenue of any for biomedical research to achieve the discovery of entirely new therapeutics over the upcoming decade,” he wrote. His nomination was supported by Dr. William G. Kaelin Jr., Howard Hughes Medical Institute Investigator and Professor of Medicine, Harvard Medical School.

Dr. Greka is currently Assistant Professor at Harvard Medical School; Institute Member at the Broad Institute of MIT and Harvard; and an Associate Physician at Brigham and Women’s Hospital (BWH), where she joined the faculty in 2012. She received her MD/PhD in 2004 from Harvard Medical School, followed by a residency in internal medicine at Massachusetts General Hospital (MGH, 2007) and a fellowship in nephrology at MGH and BWH (2009). Her work has been supported in part by the National Institute of Diabetes and Digestive and Kidney Diseases. She was a 2014 recipient of an ASCI Young Physician-Scientist Award and was elected to the ASCI in 2017.

Dr. Nijhawan is currently Assistant Professor in the Departments of Biochemistry and Hematology and Oncology at UT Southwestern Medical Center, where he joined the faculty in 2012. He received his MD/PhD in 2005 from UT Southwestern, followed by an internship and residency in internal medicine at MGH (2007) and a fellowship in medical oncology at the Dana-Farber Cancer Institute (2011). His work has been supported in part by the Sass Foundation for Medical Research, Damon Runyon Cancer Research Foundation, Harrington Discovery Institute, and the National Cancer Institute.

In addition to sharing an unrestricted award of $30,000 to advance their academic efforts, Drs. Greka and Nijhawan will be recognized on April 21, 2018, as part of the AAP/ASCI/APSA Joint Meeting (April 20-22), and they will deliver scientific talks at the 2019 Joint Meeting.

The Seldin~Smith Award, now in its third year, began with the goal of connecting the legacies of two iconic figures in medicine — Donald Seldin (UT Southwestern) and Lloyd “Holly” Smith Jr. (University of California, San Francisco) — with exceptionally creative early-career physician-scientists. The ASCI is grateful to Drs. Seldin and Smith, who provided the inspiration for this Award through their storied careers of developing generations of outstanding physician-scientists, and to the donors who have made the program possible.

Nominations were evaluated by a Selection Committee of current and former ASCI presidents: Mukesh K. Jain (Chair), Vivian G. Cheung, Charles L. Sawyers, Elizabeth M. McNally, and Stuart H. Orkin. Finalists were evaluated by an Advisory Committee comprising five physician-scientist luminaries: Joseph L. Goldstein (Chair), Michael S. Brown, Arthur Weiss, Stanley B. Prusiner, and Robert J. Lefkowitz.

The Seldin~Smith Award complements two prestigious ASCI awards (the Stanley J. Korsmeyer Award and the ASCI / Harrington Prize for Innovation in Medicine) that recognize senior physician-scientists who have made major contributions to science, mentorship, and translation of discovery to clinical impact.

Celebrating 20 years of the Stanley J. Korsmeyer Award

This year, the ASCI is celebrating the 20th anniversary of the Stanley J. Korsmeyer Award, which has become a beacon of excellence by celebrating key discoveries made by physician-scientists who are also passionate about mentoring.

At the upcoming Joint Meeting, on Friday, April 20, 5 to 5:30 p.m., the ASCI will recognize Dr. Joseph Heitman as the 2018 Korsmeyer Award recipient. His presentation for the Korsmeyer Lecture is “Natural product drug targets are conserved from model and pathogenic yeasts to humans.”

Also on Friday, April 20, Benjamin L. Ebert, MD, PhD, the 2017-2018 ASCI President, will host his President’s Reception from 6 to 7:15 p.m. in honor of this milestone for the Korsmeyer Award. The reception will feature introductory remarks from Dr. Ebert followed by reminiscences from:

  • Susan Korsmeyer, Dr. Korsmeyer’s widow and a staunch advocate for the Award and its legacy
  • Scott A. Armstrong, MD, PhD, a former trainee of Dr. Korsmeyer and currently Chair of the Department of Pediatric Oncology at the Dana-Farber Cancer Institute
  • Timothy J. Ley, MD, a former colleague of Dr. Korsmeyer and currently Associate Director for Cancer Genomics, The Genome Institute, Washington University, St. Louis

In connection with celebrating the significant history of the Award and recognizing Dr. Korsmeyer, the ASCI is seeking the support of the physician-scientist community to sustain the Award’s legacy. Your gift to the Korsmeyer Award Fund, which will be restricted to the Award, will highlight your commitment to this critical recognition and the impact it has had, and will continue to have, on the physician-scientist community.

It is an honor for me to join Susan Korsmeyer and Carnell Korsmeyer (Dr. Korsmeyer’s mother) in a combined Visionary donation toward the fund. I am pleased to recognize other initial donors: Louis J. Ptáček, MD (2015 Award recipient), James E. Crowe Jr., MD (2017 Award recipient), and Kieren Marr, MD (Chair, ASCI Development Committee).

I hope that you will be able to join us in celebrating the Stanley J. Korsmeyer Award and its legacy:

https://www.the-asci.org/awards/korsmeyer/k20

As ever, thank you for your time.

John B. Hawley
Executive Director
The American Society for Clinical Investigation

2018 omnibus appropriations: great news for research funding

Dear ASCI member,

A part of our mission as a community of physician-scientists is to advocate for medical research and for measures that sustain the pipeline of young physicians to engage in research careers. In 2017, we formed an Advocacy Committee to work more closely with FASEB and Research!America, our advocacy partner organizations. Member Alp Ikizler serves as a member of FASEB’s Board of Directors, Council member Donna Martin serves on FASEB’s Science Policy Committee, and I serve as a liaison to the FASEB Board of Directors.

Earlier this spring, Donna Martin was the ASCI representative attending FASEB’s Capitol Hill Day, meeting with representatives to convey the value of investment in the U.S. research infrastructure.

FASEB staff have agreed to work with us to generate timely updates about the activities on Capitol Hill of value to ASCI members. Following is brief detail regarding the passage of the FY 2018 omnibus appropriations bill:

At 12:21 am Friday the Senate passed the fiscal year (FY) 2018 omnibus appropriations bill by a vote of 65-32. President Trump signed the bill into law Friday afternoon. Although it could take another 30 days for the new funds to be made available to the federal agencies, we can officially celebrate the $3 billion increase for NIH, $295 million increase for NSF, $868 million increase for DOE SC, $47 million increase for veterans research, and $25 million increase for competitive agriculture research.

Please see FASEB’s summary (PDF) for more information.

Look out for more information to come.

W. Kimryn Rathmell, MD, PhD
Chair, Advocacy Committee
The American Society for Clinical Investigation
www.the-asci.org
Follow us on Twitter: www.twitter.com/the_asci

The 2018 Harrington Prize for Innovation in Medicine: Helen H. Hobbs, MD

2018 Harrington Prize awarded to Dr. Helen Hobbs, University of Texas Southwestern Medical Center, for her advancements in biomedical science

The fifth annual Harrington Prize for Innovation in Medicine has been awarded to Helen H. Hobbs, MD, investigator of the Howard Hughes Medical Institute and Professor of Internal Medicine and Molecular Genetics at the University of Texas Southwestern Medical Center.

The Harrington Prize for Innovation in Medicine, established in 2014 by the Harrington Discovery Institute at University Hospitals (UH) in Cleveland, Ohio, and The American Society for Clinical Investigation (ASCI), honors physician-scientists who have moved science forward with achievements notable for innovation, creativity, and potential for clinical application.

Dr. Hobbs is being recognized for her outstanding contributions to medicine and science. Her discovery of the link between a gene mutation (PCSK9) and lower levels of LDL, or “bad cholesterol,” is considered a major breakthrough and has improved the treatment of high cholesterol. Dr. Hobbs made the discovery when she sequenced the PCSK9 gene in subjects from a population-based study of 3,500 residents of Dallas County, Texas. She found that subjects with this particular mutation not only had lower LDL levels, but also had an 88% lower incidence of heart attacks as compared with the controls in the study. The discovery of this critical link has enabled the development of therapeutics that can effectively target the gene in order to lower LDL and the risk of heart attack.

“Dr. Hobbs’ research has had a profound impact on human health,” said Benjamin Ebert, MD, PhD, Chair of Medical Oncology at the Dana-Farber Cancer Institute, Professor of Medicine at Harvard Medical School, and 2017-2018 President of the ASCI. “Her ground-breaking discovery of PCSK9’s connection to cholesterol has led to the development of an FDA-approved therapy within 10 years, which is a remarkable achievement.”

A committee composed of members of the ASCI Council and the Harrington Discovery Institute Scientific Advisory Board reviewed nominations from leading academic medical centers from three countries before selecting the 2018 recipient.

“We are pleased to join with the ASCI to honor Dr. Hobbs for her pioneering studies in human genetics that have advanced the standard of care,” said Jonathan Stamler, MD, President of the Harrington Discovery Institute and the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation at UH Cleveland Medical Center and Case Western Reserve University School of Medicine. “Her superb work clearly exemplifies the guiding principles of The Harrington Prize, which recognizes the most innovative and creative investigators to have impacted patients’ lives.”

In addition to receiving a $20,000 honorarium, Dr. Hobbs will deliver the Harrington Prize Lecture at the 2018 AAP/ASCI/APSA Joint Meeting on April 20, 2018, and publish an essay in the Journal of Clinical Investigation.

Dr. Hobbs, Director of the Eugene McDermott Center for Human Growth and Development, received her MD from Case Western Reserve University in 1979. She is currently Director of the Dallas Heart Study, a longitudinal, multiethnic, population-based study of Dallas County in Texas. Dr. Hobbs holds the Eugene McDermott Distinguished Chair for the Study of Human Growth and Development, Philip O’Bryan Montgomery, Jr., M.D. Distinguished Chair in Developmental Biology, and the 1995 Dallas Heart Ball Chair in Cardiology Research.

The first recipient of The Harrington Prize for Innovation in Medicine, in 2014, was Dr. Harry Dietz (Johns Hopkins University School of Medicine, USA), a pediatric cardiologist and genetics researcher, for his contributions to the understanding of the biology and treatment of Marfan syndrome, a disorder leading to deadly aneurysms in children and adults. The 2015 recipient was Douglas R. Lowy, MD, Chief, Laboratory of Cellular Oncology (The National Cancer Institute, USA), in recognition of his discoveries that led to the development of the Human Papillomavirus (HPV) vaccine to prevent cervical cancer. The 2016 recipient was Jeffrey M. Friedman, MD, PhD (The Rockefeller University, USA), for his discovery of leptin, which controls feeding behavior and is used to treat related clinical disorders. In 2017, the Prize was awarded jointly to Daniel J. Drucker, MD (Mount Sinai Hospital, Canada), Joel F. Habener, MD (Massachusetts General Hospital, USA) and Jens J. Holst, MD, DMSc (University of Copenhagen, Denmark) for their discovery of incretin hormones and for the translation of these findings into transformative therapies for major metabolic diseases such as diabetes.

Harrington Discovery Institute

The Harrington Discovery Institute at University Hospitals in Cleveland, OH – part of The Harrington Project for Discovery & Development – aims to advance medicine and society by enabling our nation’s most inventive scientists to turn their discoveries into medicines that improve human health. The institute was created in 2012 with a $50 million founding gift from the Harrington family and instantiates the commitment they share with University Hospitals to a Vision for a ‘Better World’.

The Harrington Project for Discovery & Development

The Harrington Project for Discovery & Development (The Harrington Project), founded in late February 2012 by the Harrington Family and University Hospitals of Cleveland, is a $300 million national initiative built to bridge the translational valley of death. It includes the Harrington Discovery Institute and BioMotiv, a for-profit, mission-aligned drug development company that accelerates early discovery into pharma pipelines.

For more information about The Harrington Project and the Harrington Discovery Institute, visit: HarringtonDiscovery.org.

University Hospitals

Founded in 1866, University Hospitals serves the needs of patients through an integrated network of 18 hospitals, more than 40 outpatient health centers and 200 physician offices in 15 counties throughout northern Ohio. The system’s flagship academic medical center, University Hospitals Cleveland Medical Center, located on a 35-acre campus in Cleveland’s University Circle, is affiliated with Case Western Reserve University School of Medicine. The main campus also includes University Hospitals Rainbow Babies & Children’s Hospital, ranked among the top children’s hospitals in the nation; University Hospitals MacDonald Women’s Hospital, Ohio’s only hospital for women; and University Hospitals Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center. UH is home to some of the most prestigious clinical and research programs in the nation, including cancer, pediatrics, women’s health, orthopedics, radiology, neuroscience, cardiology and cardiovascular surgery, digestive health, transplantation and urology. UH Cleveland Medical Center is perennially among the highest performers in national ranking surveys, including “America’s Best Hospitals” from U.S. News & World Report. UH is also home to Harrington Discovery Institute at University Hospitals – part of The Harrington Project for Discovery & Development. UH is one of the largest employers in Northeast Ohio with 26,000 employees.

UH’s vision is “Advancing the science of health and the art of compassion,” and its mission: “To Heal. To Teach. To Discover.” Follow UH on Facebook @UniversityHospitals and Twitter @UHhospitals. For more information, go to UHhospitals.org.

The 2018 Stanley J. Korsmeyer Award: Joseph Heitman, MD, PhD

Joseph Heitman, MD, PhD, is the recipient of the 2018 American Society for Clinical Investigation’s (ASCI) Stanley J. Korsmeyer Award for his key contributions to our understanding of how eukaryotic microbial pathogens evolve, cause disease, and develop drug resistance; and his discovery of TOR and FKBP12 as targets of the immunosuppressive chemotherapeutic drug rapamycin.

Dr. Heitman received BS and MS degrees from the University of Chicago in 1984, his PhD from Rockefeller University in 1989, and his MD from Cornell University in 1992. From 1989 to 1991, he was a European Molecular Biology Organization postdoctoral fellow at the University of Basel’s Biozentrum, in the laboratory of Michael N. Hall.

Rapamycin was first isolated from the bacterium Streptomyces hygroscopicus in the early 1970s from Easter Island soil samples collected in the 1960s, in a hunt for microbes that might provide the basis for new drugs. Although rapamycin was first developed as an antifungal agent, it was found to be a powerful suppressor of the immune system and was effectively abandoned for a time. However, researchers subsequently took up the immunosuppressive qualities of rapamycin and other drugs to transform the field of organ transplantation by making recipients less susceptible to rejecting their transplants. In addition, rapamycin was found to hinder cell growth, opening its use in the treatment of cancer and in the prevention of restenosis of coronary artery stents.

As a fellow in Dr. Hall’s laboratory, Dr. Heitman focused on the mechanism of action of rapamycin and two other immunosuppressive drugs, cyclosporin A and FK506 (tacrolimus), using Baker’s yeast, Saccharomyces cerevisiae, to study the drugs’ activity. In collaboration with Rao Movva, a scientist at Sandoz Pharmaceuticals in Basel, the researchers found that rapamycin arrested yeast cell growth in a manner similar to how it arrested growth in human T- cells, supporting the idea that the drug target was the same in both yeast and human. Their isolation and analysis of drug-resistant yeast mutants led to the discovery of FKBP12 and TOR as the targets of rapamycin. Further studies revealed the TOR pathway functions to sense nutrients and govern appropriate cellular physiological responses.

Subsequently, Dr. Heitman’s research in infectious disease has defined molecular virulence determinants and revealed novel modes of sexual reproduction and drug resistance for eukaryotic pathogenic microbes. The phosphatase calcineurin (the target of cyclosporin A and FK506) was identified as a key virulence determinant conserved across human fungal pathogens, and ongoing studies are exploring new therapeutic leads. He discovered that pathogenic microbes undergo unisexual reproduction, and has studied its impact on the evolution of eukaryotic microbial pathogens and how sexual reproduction may have originally evolved. Recent studies have unveiled novel mechanisms of antimicrobial drug resistance involving epimutations that silence drug-target genes via RNAi. Beyond his own laboratory, Dr. Heitman has provided resources and insights to advance the field of fungal genetics and genomics.

Dr. Heitman has mentored numerous undergraduates, medical students, graduate students, and postdoctoral and medical fellows, many of whom have developed independent careers in medicine and basic biomedical research. Among many others, John Perfect, Andrew Alspaugh, and William Steinbach have been key collaborators in studies on fungal pathogenesis and therapeutic exploration.

Dr. Heitman’s work has been recognized by the Gustavo Cudkowicz Memorial Prize in Immunobiology, 1991; the American Society for Biochemistry and Molecular Biology’s AMGEN Award, for significant achievements in the understanding of human disease involving studies in model yeasts defining targets and modes of action for immunosuppressive drugs, 2002; the Infectious Diseases Society of America’s Squibb Award, in recognition of outstanding achievement in the field of infectious diseases, in 2003; and a National Institutes of Health / National Institute of Allergy and Infectious Diseases MERIT award for studies on unisexual reproduction of eukaryotic microbial pathogens, 2011-2021.

Dr. Heitman is an elected fellow of the Infectious Diseases Society of America (2003), the ASCI (2003), the American Academy of Microbiology (2004), the American Association for the Advancement of Science (2004), and the Association of American Physicians (2006).

Dr. Heitman joined the faculty at Duke University School of Medicine in 1992, was named a James B. Duke Professor in 2004, and appointed Chair of the Department of Molecular Genetics and Microbiology in 2009. He was an investigator of the Howard Hughes Medical Institute from 1992 to 2005 and a Burroughs-Wellcome Scholar in Molecular Pathogenic Mycology from 1998 to 2005. He has given prominent lectures, including the American Society for Microbiology Division F Lecture (2009), the Foundation Lecture for the British Society for Medical Mycology (2010), the Karling Lecture for the Mycological Society of America (2011), and the Max Delbrück Lecture for the German Genetics Society (2017); is an editor of PLOS Genetics, mBio, PLOS Pathogens, and Fungal Genetics and Biology; and has edited seven textbooks on fungal pathogens, evolution of eukaryotic microbial pathogens, genetics, and microbiology.

Message from the President

The Council recently asked the Active membership to vote on its recommendations for 2018 new members and proposed changes to the ASCI bylaws. I am pleased to write that the vote was overwhelmingly in favor of both.

The ASCI will welcome 78 new members at the upcoming AAP/ASCI/APSA Joint Meeting, April 20-22 at the Fairmont Chicago. We’ll be profiling some of our new members in the run-up to the meeting, and you can see the full list of those joining the ASCI here.

Registration for the meeting is open, and I encourage you to attend this year to experience great science, to support and mentor young physician-scientists across the career spectrum, and to connect with your colleagues.

The changes to the bylaws were focused on the Society’s publishing efforts. With these changes, the ASCI bylaws now specifically enumerate Publications and Editor Selection Committees, and they describe JCI Insight, now in its third year of publication.

Dr. Howard Rockman will remain as JCI Insight Editor through August 2019. In the coming months, the Publications Committee will be defining the application process for the next JCI Insight Editor, who will serve a five-year term beginning September 2019.

I would like to use this opportunity to thank those who contributed to the ASCI’s 2017 annual appeal, the first time the ASCI has undertaken such an effort, and to those who contributed to specific programs throughout 2017.

Beyond being grateful for this support, I am thankful for the passion and energy each of you contribute to the ASCI and the physician-scientist community in so many other ways.

I look forward to seeing you in Chicago in April.

Sincerely,


Benjamin L. Ebert, MD, PhD
2017-2018 President
The American Society for Clinical Investigation

New members, 2018

The ASCI is pleased to recognize the following 78 physician-scientists who were officially inducted into the Society at the ASCI Dinner & New Member Induction Ceremony, April 20, 2018, as part of the AAP/ASCI/APSA Joint Meeting in Chicago.

Name Institution
Omar I. Abdel-Wahab, MD Memorial Sloan Kettering Cancer Center
Prasad S. Adusumilli, MD Memorial Sloan Kettering Cancer Center
Michael S.D. Agus, MD Harvard Medical School, Boston Children’s Hospital
Susanne E. Ahmari, MD, PhD University of Pittsburgh Medical Center
Gregory T. Armstrong, MD, MSCE St. Jude Children’s Research Hospital
Jodie L. Babitt, MD Harvard Medical School, Massachusetts General Hospital
Rebecca Marlene Baron, MD Harvard Medical School, Brigham & Women’s Hospital
Ethan Martin Basch, MD, MPhil, MSc University of North Carolina at Chapel Hill
Murat Bastepe, MD, PhD Harvard Medical School, Massachusetts General Hospital
Sudha B. Biddinger, MD, PhD Harvard Medical School, Boston Children’s Hospital
Alessandra Biffi, MD Harvard Medical School, Boston Children’s Hospital
Paul Laszlo Bollyky, MD, PhD Stanford University School of Medicine
David T. Breault, MD, PhD Harvard Medical School, Boston Children’s Hospital
Kathleen H. Burns, MD, PhD Johns Hopkins University School of Medicine
Yu Chen, MD, PhD Memorial Sloan Kettering Cancer Center
Sharlene M. Day, MD University of Michigan Medical School
Arjun Deb, MD University of California, Los Angeles, David Geffen School of Medicine
Ian Harm de Boer, MD, MS University of Washington School of Medicine
Joshua C. Denny, MD, MS Vanderbilt University School of Medicine
Luis A. Diaz, Jr., MD Memorial Sloan Kettering Cancer Center
Jeremy S. Dittman, MD, PhD Weill Cornell Medical College
Abhinav Diwan, MBBS Washington University School of Medicine in St. Louis
Robert C. Doebele, MD, PhD University of Colorado School of Medicine
Alexandre Y. Dombrovski, MD University of Pittsburgh School of Medicine
XinQi Dong, MD, MPH Rutgers University, The State University of New Jersey
Oliver Eickelberg, MD University of Colorado School of Medicine
Marni Joy Falk, MD University of Pennsylvania School of Medicine
Matthew Scott Freiberg, MD, MSc Vanderbilt University School of Medicine
Jennifer F. Friedman, MD, PhD, MPH Brown University Medical School
Daniel M. Greif, MD Yale School of Medicine
Jan Grimm, MD, PhD Memorial Sloan Kettering Cancer Center
Cary P. Gross, MD Yale School of Medicine
Saptarsi M. Haldar, MD University of California, San Francisco, School of Medicine
Megan R. Haymart, MD University of Michigan Medical School
Maureen Renee Horton, MD Johns Hopkins University School of Medicine
Leora I. Horwitz, MD, MHS New York University School of Medicine
Yujin Hoshida, MD, PhD Icahn School of Medicine at Mount Sinai
Susan S. Huang, MD, MPH University of California, Irvine, School of Medicine
Arti Hurria, MD City of Hope Medical Center
Theodore (Jack) Iwashyna, MD, PhD University of Michigan Medical School
Antonio Jimeno, MD, PhD University of Colorado Health Sciences Center
Daniel H. Kaplan, MD, PhD University of Pittsburgh School of Medicine
Keith S. Kaye, MD, MPH University of Michigan Medical School
Alex Kentsis, MD, PhD Memorial Sloan Kettering Cancer Center
Young J. Kim, MD, PhD Vanderbilt University School of Medicine
Rahul M. Kohli, MD, PhD University of Pennsylvania School of Medicine
Suneil K. Koliwad, MD, PhD University of California, San Francisco, School of Medicine
Margot Beth Kushel, MD University of California, San Francisco, School of Medicine
Bonnie Ky, MD, MSCE University of Pennsylvania School of Medicine
Maciej S. Lesniak, MD, MHCM Northwestern University Feinberg School of Medicine
Jonathan H. Lin, MD, PhD University of California, San Diego, School of Medicine
Nehal N. Mehta, MD, MSCE NIH, National Heart, Lung, and Blood Institute
Lloyd S. Miller, MD, PhD Johns Hopkins University School of Medicine
Ann Mullally, MD Harvard Medical School, Brigham & Women’s Hospital
Peter A. Nigrovic, MD Harvard Medical School
John Erik Pandolfino, MD, MSCI Northwestern University Feinberg School of Medicine
Eirini P. Papapetrou, MD, PhD Icahn School of Medicine at Mount Sinai
Chirag R. Parikh, MD, PhD Yale School of Medicine
Ben Ho Park, MD, PhD Johns Hopkins University School of Medicine
Sachin Patel, MD, PhD Vanderbilt University School of Medicine
Ganesh V. Raj, MD, PhD University of Texas Southwestern Medical Center
Rajat Rohatgi, MD, PhD Stanford University School of Medicine
Matthew R. Rosengart, MD, MPH University of Pittsburgh School of Medicine
Joseph Solomon Ross, MD, MHS Yale School of Medicine
Vijay Sankaran, MD, PhD Harvard Medical School, Boston Children’s Hospital
Simone Sanna-Cherchi, MD Columbia University College of Physicians & Surgeons
Padmanee Sharma, MD, PhD University of Texas M.D. Anderson Cancer Center
Donald C. Sheppard, MD McGill University Faculty of Medicine
Brad Spellberg, MD University of Southern California Keck School of Medicine
Charlotte J. Sumner, MD Johns Hopkins University School of Medicine
David T. Teachey, MD Children’s Hospital of Philadelphia
Amal N Trivedi, MD, MPH Brown University Medical School
Minang Mintu Turakhia, MD, MAS Stanford University School of Medicine
Cameron J. Turtle, MBBS, PhD Fred Hutchinson Cancer Research Center
John S. Welch, MD, PhD Washington University School of Medicine in St. Louis
Robert B. West, MD, PhD Stanford University School of Medicine
Paul B. Yu, MD, PhD Harvard Medical School, Brigham & Women’s Hospital
Kareem A. Zaghloul, MD, PhD NIH, National Institute of Neurological Disorders and Stroke

Call for Council nominations, 2018

The Society is seeking nominations for the following vacancies on the ASCI Council (all terms begin and end in the spring): Vice President (4-year term, 2018-2022), Secretary-Treasurer-elect (3-year term, 2018-2021, with the first year served as a regular Councilor), and Councilor (3-year term, 2018-2021).

All Council members are expected to support the activities of and attend the ASCI annual meeting, and to participate in the general governance of the Society, including two in-person meetings (fall and spring, coordinate with the annual meeting), and conference calls (typically every other month). All Council members participate in the review of membership nominations.

The Vice President transitions to President-Elect in year 2 and President in year 3. For the 2nd through 4th years of this position, this member is expected to participate significantly in matters related to the Joint Meeting. In the Presidential year (year 3), the member convenes a face-to-face Council meeting and oversees related review processes for nominations, notably including those to membership. The President works closely with the Association of American Physicians to create the annual meeting program, and the member presents the traditional Presidential Address at the meeting. In year 4, the President transitions to Immediate Past President, serving as an advisor to the current President and with full Council responsibilities and privileges.

The Council is supported by an Executive Director, Managing Director, and other staff members who oversee the day-to-day operations of the Society and effect initiatives as directed by the Council. For details on Officers and Councilors, see the ASCI Bylaws.

Members who will be 55 or younger in 2021 are eligible for nomination. The Society encourages you to keep under consideration the importance of diversity among the Council. Nominations may be submitted online through January 17, 2018, at 11:59 PM EST and consist of a 250-word summary of accomplishments accompanied by an NIH-style brief biosketch (PDF only). If the nomination is intended for a specific vacancy, note this in the nomination comments.

Members must submit nominations through their member accounts. (Please note: Self-nomination is no longer available for Council nominations.)